AstraZeneca shares rockets after Brilinta drug gives promise of future brilliance

Comments Off on AstraZeneca shares rockets after Brilinta drug gives promise of future brilliance

Shares rose 50.5p — 1.07% — to 4767.25p, after a clinical trial of 21,000 patients found that Brilinta — which prevents blood clotting and which AstraZeneca reckons could hit annual sales of £2 billion — cuts the risk of death or heart attack in patients with a history of previous attacks more than 12 months after their first episode.

 

Astra’s boss, Pascal Soriot, had named Brilinta as crucial for the pharma giant to hit his target — set during the takeover battle — of annual revenues of $45 billion (£29.6 billion) by 2023.

The City reckoned that was a tough ask, as Brilinta’s sales in the first nine months of last year were only $343 million, and analysts said the pill would only become a best-seller if it reached a wider range of patients.

Now the latest trials suggest the blood-thinning drug benefits patients more than a year after they have suffered a heart attack, suggesting users could take Brilinta for longer.

The findings could more than double the number of people eligible to use the medicine.

At present, patients recovering from a heart attack tend to take anti-clotting drugs such as the generic alternative to Plavix, which was developed by Sanofi and Bristol-Myers Squibb, for about 12 months after an attack, before moving onto aspirin.

Source Article from http://www.standard.co.uk/business/business-news/astrazeneca-shares-rockets-after-brilinta-drug-gives-promise-of-future-brilliance-9977713.html

January 15, 2015 |
Copyright © 2018 LondonBusinessLink.co.uk. All Rights Reserved. LondonBusinessLink.co.uk
WordPress Directory Theme

Classified Ads Software

We use cookies to ensure that we give you the best experience on our website.
More about our cookies
Ok
Skip to toolbar